Clinical application of enoxaparin

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 3, 2004, Pages 321-337

  Hofmann, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute coronary syndrome; Atrial fibrillation; Cost effectiveness; Deep vein thrombosis; Electrical cardioversion; Low molecular weight heparin; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ABCIXIMAB; ALPHAPARIN; ANTICOAGULANT AGENT; CERTOPARIN; CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PHENPROCOUMON; PLACEBO; PROSULF; PROTAMINE SULFATE; STREPTOKINASE; TENECTEPLASE; TINZAPARIN; TIROFIBAN; WARFARIN;

AMBULATORY CARE; ANTICOAGULATION; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMATOMA; HOME CARE; HOSPITAL CARE; HUMAN; ORTHOPEDIC SURGERY; REVIEW; SURGICAL PATIENT; THROMBOCYTOPENIA; VASCULAR SURGERY; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL ISCHEMIA; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 2542486654     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.3.321     Document Type: Review

References (123)

1. Weitz J. Low-molecular-weight heparins. N. Engl. J. Med. 337, 688-698 (1997).
2. Hirsh J, Levine M. Low molecular weight heparin. Blood 79, 1-17 (1992).
3. Olson S, Shore J. Demonstration of a two-step reaction mechanism for inhibtion of α-thrombin by antithrombin III and identification of the step affected by heparin. J. Biol. Chem. 257, 4891-4895 (1982).
4. Noble S, Spencer C. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 56(2), 259-272 (1998).
5. Fareed J, Hoppenstaedt D, Bick R. An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemost. 26, 5-21 (2000).
6. Massonnet-Castel S, Pelissier E, Bara L et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extra-corporal circulation. Haemostasis 16, 139-146 (1986).
7. Sanson B, Lensing A, Prins M et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb. Haemost. 81, 668-672 (1999).
8. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97, 251-256 (1998).
9. Cohen M, Theroux P, Weber S et al. Combination with tirofiban and enoxaparin in acute coronary syndromes. Int. J. Cardiol. 71, 273-2781 (1999).
10. Kiesz R, Buszman P, Martin J et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial. Circulation 103, 26-31 (2001).
11. Currier J, Pow T, Haudenschild C et al. Low molecular weight heparin (enoxaparin) reduced restenosis following angioplasty in the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 17, B118-B125 (1991).
12. Bara L, Billaud E, Gramond G et al. Comparative pharmakokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb. Res. 39, 631-636 (1985).
13. Frydman A, Bara L, Le Roux Y et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J. Clin. Pharmacol. 28, 609-618 (1988).
14. Collignon F, Frydman A, Caplain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 73, 630-640 (1995).
15. Cadroy Y, Pourrat J, Baladre M et al. Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thromb. Res. 63, 385-390 (1991).
16. Sanderink G, Guimart C, Ozoux M et al. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment. JACC 37(Suppl. A), 1A-648A (2001).
17. Gillum R. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am. Heart J. 114, 1262-1264 (1987).
18. Geerts W, Heit J, Clagett J et al. Prevention of venous thromboembolism. Chest 119, S132-S175 (2001).
19. Samama M, Bernard P, Bonnardot J et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br. J. Surg. 75, 128-131 (1988).
20. Anderson F, Wheeler H, Goldberg R et al. The prevalence of risk factor for venous thromboembolism among hospital patients. Arch. Intern. Med. 152, 1660 (1992).
21. Bergqvist D, Lindblad B. Incidence of venous thromboembolism in medical and surgical patients. In: Prevention of Venous Thromboembolism. Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH (Eds). Med-Orion, London, UK (1994).
22. Statement EC. Prevention of venous thromboembolism. Int. Angiol. 11, 151 (1992).
23. Keaton C. Duration of venous thromboembolism prophylaxis after surgery. Chest 124, S386-S392 (2003).
24. Mismetti P, Laporte-Simitsidis S, Tardy B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular weight heparins: a meta-analysis of randomized clinical trials. Thromb. Haemost. 83, 14-19 (2000).
25. Kakkar V, Howe C, Flanc C et al. Natural history of postoperative deep vein thrombosis. Lancet 2(7614), 230-232 (1969).
26. Hull R, Delmose T, Genton E et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med. 301(16), 855-858 (1979).
27. Gazzaniga G, Angelini G, Pastorino G et al. Enoxaparin in the prevention of deep vein thrombosis after major surgery: multicentric study. The Italian Study group. Int. Surg. 78, 271-275 (1993).
28. Nurmohamed M, Verhaeghe R, Haas S et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am. J. Surg. 169, 567-571 (1995).
29. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicenter trial with venographic assessment. Br. J. Surg. 84, 1099-1103 (1997).
30. Bergqvist D, Agnelli G, Cohen A et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 346, 975-980 (2002).
31. Farkas J, Chapuis C, Combe S et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing vascular surgery. Eur. J. Vasc. Surg. 7, 554-560 (1993).
32. Samama M, Gigou F, Ill P et al. Low-molecular-weight heparin versus unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Ann. Vasc. Surg. 9, S45-S53 (1995).
33. Agnelli G, Piovella F, Buonchristiani P et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N. Engl. J. Med. 339, 80-85 (1998).
34. Colwell C, Spiro T, Trowbridge A et al. Use of enoxaparin, a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis after elective hip replacement. J Bone Joint Surg. Br. 76, 3-14 (1994).
35. Planes A, Vochelle N, Darmon J et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 348, 224-228 (1996).
36. Spiro TE, Colwell CW, Gardiner GA et al. A clinical trial comparing the efficacy and safety of enoxaparin a low molecular weight heparin for the prevention of deep venous thrombosis after elective knee replacement surgery. J. Gen. Intern. Med. 9, 36 (1994).
37. Colwell C, Spiro T, Trowbridge A et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin. Orthop. 321, 19-27 (1995).
38. Geerts W, Jay R, Code K et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N. Engl. J. Med. 335, 701-707 (1996).
39. Barbour L, Kick S, Steiner J et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. 170, 862-869 (1994).
40. Ginsberg J, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 114, S524-S530 (2001).
41. Casele H, Laifer S. Prospective evalution of bone density in pregnant women receiving low molecular weight heparin enoxaparin sodium. J. Matern. Fetal Med. 9, 122-125 (2000).
42. Borel-Derlon A, Borg J, Boudignet O et al. Assessment of a LMWH (enoxaparin) safety during pregnancy: a retrospective study of 624 pregnancies. Thromb. Haemost. 82, 1550 (1999).
43. Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated with enoxaparin. Thromb. Haemost. 83, 693-697 (2000).
44. Lev-Ran O, Kramer A, Gurevitch J et al. Low-molecular weight heparin for prosthetic heart valves: treatment failure. Ann. Thorac. Surg. 69, 264-265 (2000).
45. Idir M, Madonna F, Roudaut R. Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical heart valve prosthesis during low-molecular-weight heparin therapy. J. Heart Valve Dis. 8, 303-304 (1999).
46. Berndt N, Khan I, Gallo R. A complication in anticoagulation using low-molecular weight heparin in a patient with mechanical heart valve prosthesis. A case report. J. Heart Valve Dis. 9, 844-846 (2000).
47. Ginsberg J, Chan W, Bates S et al. Anticoagulation in pregnant women with mechanical heart valves. Arch. Intern. Med. 163, 694-698 (2003).
48. Lechler E, Schramm W, Flosbach C et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular weight heparin (enoxaparin). Haemostasis 26, 49-56 (1996).
49. Sarrama M, Cohen A, Darmon J et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. Med. 341, 793-800 (1999).
50. Kleber F, Witt C, Vogel G et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am. Heart J. 145, 614-621 (2003).
51. Dechelette E, Pouzol P, Jurkovitz C et al. Utilisation de l'ènoxaparine pour l'anticoagulation du curcuit extracorporel des hèmodialyses a haut risque. J. Mal. Vasc. 12, 105-107 (1987).
52. Gamberoni J. Utilisation d'une hèparine des bas poids molèculaire (enoxaparine) chez I'hèmodialysis chronique à risque hèmorrhagique. Ann. Med. Nancy 28, 187-189 (1989).
53. Leizorovicz A. Comparison of the safety and efficacy of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs 52, 30-37 (1996).
54. Leizorovicz A, Simonneau G, Decousus H et al. Comparison of efficacy and safety of low-molecular-weight heaprins and unfractionated heparin in initial treatment of deep veinous thrombosis: a meta-analysis. Br. Med. J. 309, 299-304 (1994).
55. Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch. Intern. Med. 153, 1541-1546 (1993).
56. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N. Engl J. Med. 334, 677-681 (1996).
57. Merli G, Spiro T, Olsson C et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. 134, 191-202 (2001).
58. Warkentin T, Levine M, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330-1335 (1995).
59. Ardissino D, Merlini P, Ariens R et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349, 769-771 (1997).
60. Toschi V, Gallo R, Lettino M et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95, 594-599 (1997).
61. Ardissino D, Merlini P, Gamba G et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 93, 1634-1639 (1996).
62. Antman E, Handin R. Low-molecular weight heparins: an intriguing new twist with profound implications. Circulation 98, 287-289 (1998).
63. Merlini P, Bauer K, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90, 61-68 (1994).
64. Braunwald E, Antman E, Beasley J et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practive guidelines (committee on the management of patients with unstabe angina). Circulation 102, 1193-1209 (2000).
65. Bertrand M, Simoons M, Fox K et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendation of the Task Force of the European Society of Cardiology. Eur. Heart J. 21, 1406-1432 (2000).
66. Cohen M, Demers C, Gurfinkel E et al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 337, 447-452 (1997).
67. Antman E, McCabe C, Gurfinkel E et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100, 1593-1601 (1999).
68. Antman E, Cohen M, Radley D et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta analysis. Circulation 100, 1602-1608 (1999).
69. Goodman S, Cohen M, Bigonzi F et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events. J. Am. Coll. Cardiol. 36, 693-698 (2000).
70. Klein W, Buchwald A, Hillis S et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease study (FRIC) [erratum in Circulation 97, 413]. Circulation 96, 61-68 (1998).
71. FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur. Heart J. 20, 1553-62 (1999).
72. Michalis L, Katsouras C, Papmichael N et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am. Heart J. 146, 304-30 (2003).
73. Ross A, Molhoek P, Lundergan C et al. Radnomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104, 648-652 (2001).
74. Simoons M, Krzeminska-Pakula M, Alonso A et al. Does coronary artery patency improve with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur. Heart J. 23, 1282-1288 (2002).
75. The Assessment of the Safety and Efficacy of a New Thrombolytic Regiment (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 338, 605-613 (2001).
76. Antman E, Louwerenburg H, Baars H et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105, 1642-1649 (2002).
77. Collet J, Montalescot G, Lison L et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103, 658-663 (2001).
78. Ferguson J, Antman E, Bates E et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study. J. Am. Coll. Cardiol. 37, A1-A648 (2001).
79. Feinberg LJ, Blackshear J, Laupacis A et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch. Intern. Med. 155, 469-473 (1995).
80. Weinberg D, Mancini J. Anticoagulation for cardioversion in atrial fibrillation. Am. J. Cardiol. 63 (1989).
81. Bjerkelund C, Orning O. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am. J. Cardiol. 23, 208-216 (1969).
82. Arnold A, Mick M, Mazurek R et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. 19, 851-855 (1992).
83. Fuster V, Ryden L, Asinger R et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104, 2118-2150 (2001).
84. Klein A, Grimm R, Murray R et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Engl. J. Med. 344, 1411-1420 (2001).
85. Stellbrink C, Nixdorff U, Hofmann T et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of non-valvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109, 997-1003 (2004).
86. Stellbrink C, Hanrath P, Nixdorff U et al. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion - rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Z. Kardiol. 91, 249-254 (2002).
87. Drummond M, Aristides M, Davies L. Economic evaluation of heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br. J. Surg. 81, 1742-1746 (1994).
88. Hawkins D, Langley P, Krueger K. Pharmaeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am. J. Health. Syst. Pharm. 54, 1185-1190 (1997).
89. Menzin J, Richner R, Huse D et al. Prevention of deep vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmaeconomic evaluation. Ann. Pharmacother. 28, 271-275 (1994).
90. Marchetti M, Liberate, N, Ruperto N et al. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica 84, 730-737 (1999).
91. Bergqvist D, Jönsson B. Cost-effectiveness of prolonged administration of a low-molecular weight heparin for the prevention of deep vein thrombosis (DVT) following total hip replacement. Value Health 2, 288-294 (1999).
92. Etchells E, McLeod R, Geerts W et al. Economic analysis of low-dose heparin vs. the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch. Intern. Med. 159, 1221-1228 (1999).
93. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economical appraisal. Pharamacoeconomics 8, 91-99 (1995).
94. Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br. J. Surg. 83, 1548-1552 (1996).
95. Pechevis M, Detournay B, Pribil C et al. Economic evaluation of enoxaparin versus placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health 3, 389-396 (2001).
96. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am. J. Health Syst. Pharm. 54, 1968-1972 (1997).
97. Groce III J. Patient outcomes and cost analysis associated with an out-patient deep venous thrombosis treatment program. Pharamacotherapy 18, S175-S180 (1998).
98. Gould M, Dembitzer A, Sanders G et al. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis: a cost-effectiveness analysis. Ann. Intern. Med. 130, 789-799 (1999).
99. O'Brien B, Levine M, Willan A et al. Economic evaluation of outpatient treatment with low molecular weight heparin for proximal vein thrombosis. Arch. Intern. Med. 159, 2298-2304 (1999).
100. Bossuyt P, van den Belt A, Prins M. Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Haemostasis 94, 65-68 (1998).
101. Rodger M, Bredeson C, Wells P et al. Cost-effectiveness of low-molecular weight heparin and unfractionated heparin in treatment of deep vein thrombosis. Can. Med. Assoc. J. 159, 931-938 (1998).
102. Estrada C, Mansfield C, Heudebert G. Cost-effectiveness of low-molecular weight heparin in the treatment of proximal deep vein thrombosis. J. Gen. Intern. Med. 15, 108-115 (2000).
103. Hull R, Pineo G, Raskob G. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis 28, 8-16 (1998).
104. Hull R, Raskob G, Pineo G et al. Subcutaneous low-molecular-weight heparin versus warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch. Intern. Med. 157, 289-294 (1997).
105. Balen R, Marra C, Zed P et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital persepctive. Pharamacoeconomics 16, 533-542 (1999).
106. Mark D, Cowper P, Berkowitz S et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 97, 1702-1707 (1998).
107. Fox K, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br. J. Cardiol. 5, 92-105 (1998).
108. Detournay B, Huet X, Fagnani F et al. Economic evaluation of enoxparin sodium versus heparin in unstable angina. Pharamacoeconomics. 18, 83-89 (2000).
109. Nurmohamed M, Rosendaal F, HF B. Low-molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet 340, 152-156 (1992).
110. Eriksson B, Bauer K, Lassen M, Turpie A, for the Steering Committee of the Pentasaccharide in Hip-fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention in venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345, 1298-1304 (2001).
111. Lassen M, Bauer Y, Eriksson B, Turpie A, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) steering committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 359, 1715-1720 (2002).
112. Bauer K, Eriksson B, Lassen M, Turpie A, for the steering committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345, 1305-1310 (2001).
113. Turpie A, Bauer K, Eriksson B, Lassen M, for the PENTHALON 2000 study steering committee. Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet 359, 1721-1726 (2002).
114. Turpie A, Bauer K, Eriksson B, Lassen M. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch. Intern. Med. 162, 1833-1840 (2002).
115. Haas S, Flosbach C. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. Semin. Thromb. Hemost. 19, 164-173 (1993).
116. Planes A, Vochelle N, Mazas F et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb. Haemost. 60, 407-410 (1988).
117. Borris L et al. Low-molecular-weight heparin (enoxaparin) versus dextran 70 - the prevention of postoperative deep vein thrombosis after total hip replacement. Arch. Intern. Med. 151, 1621-1624 (1991).
118. Rader C, Kramer C, König A et al. Comparison between low-molecular and unfractionated heparin in the prevention of thrombosis in patients with total endoprosthetic replacement of hip and knee joint. Z. Orthop. 135, 52-57 (1997).
119. Samama M, Clergue F, Barre J et al. Low molecular weight heparin associated with spinal anesthesia and gradual compression stockings in total hip replacement surgery. Br. J. Anaesth. 78, 660-665 (1997).
120. Turpie A, Levine M, Hirsh J et al. A randomized controlled trial of low-molecular-weight heparin (Enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N. Engl. J. Med. 315, 925-929 (1986).
121. Levine M, Hirsh J, Gent M et al. Prevention of deep vein thrombosis after elective hip surgery - a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann. Intern. Med. 114, 545-551 (1991).
122. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side effects of clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul. Fibrinol. 4, 33-35 (1993).
123. Planes A, Samama M, Lensing A. Prevention of deep venous thrombosis after hip replacement. Comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb. Haemost. 81, 22-25 (1999).